Astrazeneca PLC (NYSE:AZN) – Research analysts at Jefferies Group cut their FY2016 earnings per share estimates for Astrazeneca PLC in a research report issued to clients and investors on Thursday. Jefferies Group analyst J. Holford now expects that the firm will earn $2.01 per share for the year, down from their prior forecast of $2.07. Jefferies Group currently has a “Buy” rating on the stock. Jefferies Group also issued estimates for Astrazeneca PLC’s FY2017 earnings at $2.03 EPS.
Astrazeneca PLC (NYSE:AZN) last announced its quarterly earnings results on Thursday, July 28th. The company reported $0.83 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.76 by $0.07. Astrazeneca PLC had a return on equity of 28.02% and a net margin of 9.23%. The firm earned $5.60 billion during the quarter, compared to analyst estimates of $5.56 billion. During the same quarter in the previous year, the business earned $1.21 EPS. Astrazeneca PLC’s revenue for the quarter was down 4.0% compared to the same quarter last year.
Several other equities research analysts also recently weighed in on the stock. Shore Capital reiterated a “hold” rating on shares of Astrazeneca PLC in a research note on Wednesday, July 27th. Bank of America Corp. reiterated a “buy” rating and set a $36.65 target price on shares of Astrazeneca PLC in a research note on Monday, July 18th. Citigroup Inc. reiterated a “buy” rating on shares of Astrazeneca PLC in a research note on Friday, September 23rd. Berenberg Bank reiterated a “buy” rating on shares of Astrazeneca PLC in a research note on Sunday, September 11th. Finally, Beaufort Securities reiterated a “hold” rating on shares of Astrazeneca PLC in a research note on Friday, August 26th. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. Astrazeneca PLC presently has a consensus rating of “Hold” and a consensus price target of $37.56.
Shares of Astrazeneca PLC (NYSE:AZN) opened at 30.73 on Monday. Astrazeneca PLC has a 12-month low of $26.97 and a 12-month high of $35.04. The company has a 50-day moving average price of $32.81 and a 200 day moving average price of $30.93. The firm has a market capitalization of $77.75 billion, a PE ratio of 35.12 and a beta of 0.75.
Institutional investors have recently made changes to their positions in the stock. Forester Capital Management LTD raised its position in shares of Astrazeneca PLC by 68.4% in the first quarter. Forester Capital Management LTD now owns 3,200 shares of the company’s stock worth $109,000 after buying an additional 1,300 shares during the period. First Interstate Bank raised its position in shares of Astrazeneca PLC by 233.3% in the second quarter. First Interstate Bank now owns 3,900 shares of the company’s stock worth $118,000 after buying an additional 2,730 shares during the period. Synovus Financial Corp raised its position in shares of Astrazeneca PLC by 29.7% in the second quarter. Synovus Financial Corp now owns 4,372 shares of the company’s stock worth $132,000 after buying an additional 1,000 shares during the period. Fifth Third Bancorp raised its position in shares of Astrazeneca PLC by 2.3% in the second quarter. Fifth Third Bancorp now owns 4,631 shares of the company’s stock worth $140,000 after buying an additional 103 shares during the period. Finally, Integrated Investment Consultants LLC raised its position in shares of Astrazeneca PLC by 6.1% in the second quarter. Integrated Investment Consultants LLC now owns 4,756 shares of the company’s stock worth $144,000 after buying an additional 275 shares during the period. Institutional investors own 11.46% of the company’s stock.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.